In type 1 diabetes, the pancreas fails to produce insulin, which is a hormone required for cellular uptake and metabolism of glucose
However, other patients prefer to stop taking medications completely when they reach their weight-loss goals
However, the clinical decision about how to stop tirzepatide extends beyond simple pharmacology
A 2025 retrospective cohort study found that tirzepatide was associated with a 30% to 45% lower risk of ED compared to sitagliptin, injectable semaglutide, and dulaglutide
Rare and serious side effects Other than the common side effects of compounded semaglutide mentioned above, some users may experience other side effects, such as: Hypoglycemia (low blood sugar): Semaglutide not only decreases appetite but also lowers blood sugar levels in patients with diabetes, increasing the risk of hypoglycemia